对于更准确的痴呆症诊断工作的长期成本效益
Pieter J van der Veere1,2,3, Hana M Broulikova4,5, Jeroen Hoogland2
1Alzheimer Center and Department of Neurology Amsterdam Neuroscience, Amsterdam UMC Amsterdam the Netherlands.
Alzheimer's & dementia (Amsterdam, Netherlands)
|November 6, 2025
概括
在痴呆症诊断中添加粉样质正电子发射断层扫描 (PET) 可能是具有成本效益的. 使用PET与更长的社区和整体生存时间有关,延长社区时间的成本效益概率为76%.
科学领域:
- 神经学 神经学
- 卫生经济学 卫生经济学
背景情况:
- 准确的痴呆症诊断对于长期的临床和经济结果至关重要.
- 关于先进诊断工具的成本效益存在不确定性.
研究的目的:
- 评估将粉样质正子发射断层扫描 (PET) 纳入标准记忆诊所诊断工作中的成本效益,在5年内.
- 评估粉样PET对患者存活时间和社区生活时间的影响.
主要方法:
- 一项观察性队列研究将接受粉样蛋白PET (n=440) 的参与者与没有接受阿姆斯特丹痴呆症队列 (n=460) 的参与者进行了比较.
- 使用反向概率权重来平衡两组之间的共变量.
- 成本效益分析集成的数据在社区时间,整体存活率和医疗保健费用.
主要成果:
- 粉样蛋白PET参与者在社区中表现出更长的时间 (0.26年) 和整体存活时间 (0.15年).
- 在医疗保险或总成本 (包括制度化) 中没有观察到统计学意义上的差异.
- 不确定性分析表明,在2530欧元的支付意愿值下,粉胺PET在延长社区时间方面具有成本效益的概率为76%.
结论:
- 这些发现表明,在记忆诊所设置中使用粉样蛋白PET可能是一个具有成本效益的诊断策略.
- 粉样蛋白PET的使用与患者在生存和社区生活方面改善的结果有关.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.9K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Documentation of Nursing Diagnosis
1.6K
The nurse documents nursing diagnoses and enters them into the patient record. The identified patient's nursing diagnosis is either written out with a plan of care or entered into the electronic health record.
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...
1.6K
Dementia
503
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
503
